ZXEREX-Safe
Commercial- Indications
- Impairment screening
Company intelligence / Profile preview
ZXEREX has developed and commercialized rapid, non-invasive AI-driven screening tools to detect temporary neurological impairment from drugs or fatigue. Clinical studies have been conducted at major institutions including SUNY Downstate Medical Center and Mayo Clinic. The technology is validated for detecting acute effects of cannabis, opioids, and sleep deprivation on the oculomotor system[1][3].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zxerex.